August 25, 2022A Note from Dr. Robert Stout, CRL Chief Scientific Officer & Co-Founder The below commentary from Michael Fulks, MD, is… Read More
Tags: Alzheimers, Cardiovascular risk, Dementia, Life expectancy, Life Insurance
October 1, 2021Dr. Michael Fulks comments on the results of a recent study of Donanemab, an antibody that targets the amyloid-β (Aβ)… Read More
Tags: Alzheimers, Cardiovascular, Dementia, Risk
February 18, 2020Dr. Michael Fulks is a Medical Director for Clinical Reference Laboratory (CRL). He is an expert commentator on core issues… Read More
Tags: Alzheimers, Cardiovascular Disease, Dementia, Life Insurance, Underwriting